Kies je regio
Selecteer de regio die het beste past bij je locatie of voorkeuren.
International
Sverige
Norge
Danmark
Suomi
United Kingdom
Deutschland
France
België
Nederland
Österreich
Schweiz
Italia
España
Kies je sitetaal
Deze instelling regelt de taal van de gebruikersinterface, inclusief knoppen, menu's en alle tekst op de site. Selecteer je voorkeurstaal voor de beste browse-ervaring.
Engels
English
Zweeds
Svenska
Noors
Norsk
Deens
Dansk
Fins
Suomi
Duits
Deutsch
Frans
Français
Nederlands
Nederlands
Italiaans
Italiano
Spaans
Español
Kies de talen voor vacatures
Selecteer de talen voor vacatures die je wilt zien. Deze instelling bepaalt welke vacatures aan jou worden getoond.
The two founders still own approximately 75% of the company, the remainder is owned by key persons within the organization. The company is devoted to research and development of bone regenerative technologies and biomaterials. The company is performing early-stage, pre-clinical in vitro and animal studies and all of its inventions are within the field described above. The company’s main assets next to its researchers are its patents and patent applications. Since its inception, the company has successfully developed and licensed out/sold several patent portfolios to major players within the dental implant industry. The Company is focusing all its R & D on its three new technologies, a titanium based ceramic bone graft material (NuBone®), a synthetic peptide family (NuPep™) and a paste for peri-implantitis treatment (NuGel™).